Skip to main content
Top
Published in: Diabetologia 5/2017

Open Access 01-05-2017 | Review

Genetics of obesity: can an old dog teach us new tricks?

Author: Giles S. H. Yeo

Published in: Diabetologia | Issue 5/2017

Login to get access

Abstract

At one level, obesity is clearly a problem of simple physics, a result of eating too much and not expending enough energy. The more complex question, however, is why do some people eat more than others? Studies of human and mouse genetics over the past two decades have uncovered a number of pathways within the brain that play a key role in the control of food intake. A prime example is the leptin–melanocortin pathway, which we now know greatly contributes to mammalian appetitive behaviour. However, genetic disruption of this pathway remains rare and does not represent the major burden of the disease that is carried by those of us with ‘common obesity’. In recent years, genome-wide association studies have revealed more than 100 different candidate genes linked to BMI, with most (including many components of the melanocortin pathway) acting in the central nervous system and influencing food intake. So while severe disruption of the melanocortin pathway results in severe obesity, subtle variations in these genes influence where you might sit in the normal distribution of BMI. As we now enter this ‘post-genomics’ world, can this new information influence our treatment and management of obese patients?
Appendix
Available only for authorised users
Literature
2.
go back to reference Stunkard AJ, Harris JR, Pedersen NL, McClearn GE (1990) The body-mass index of twins who have been reared apart. N Engl J Med 322:1483–1487CrossRefPubMed Stunkard AJ, Harris JR, Pedersen NL, McClearn GE (1990) The body-mass index of twins who have been reared apart. N Engl J Med 322:1483–1487CrossRefPubMed
3.
go back to reference Yeo GS, Heisler LK (2012) Unraveling the brain regulation of appetite: lessons from genetics. Nat Neurosci 15:1343–1349CrossRefPubMed Yeo GS, Heisler LK (2012) Unraveling the brain regulation of appetite: lessons from genetics. Nat Neurosci 15:1343–1349CrossRefPubMed
4.
5.
go back to reference Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372:425–432CrossRefPubMed Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372:425–432CrossRefPubMed
6.
go back to reference Montague CT, Farooqi IS, Whitehead JP et al (1997) Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387:903–908CrossRefPubMed Montague CT, Farooqi IS, Whitehead JP et al (1997) Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387:903–908CrossRefPubMed
7.
go back to reference Farooqi IS, Jebb SA, Langmack G et al (1999) Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 341:879–884CrossRefPubMed Farooqi IS, Jebb SA, Langmack G et al (1999) Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 341:879–884CrossRefPubMed
8.
go back to reference Heymsfield SB, Greenberg AS, Fujioka K et al (1999) Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282:1568–1575CrossRefPubMed Heymsfield SB, Greenberg AS, Fujioka K et al (1999) Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282:1568–1575CrossRefPubMed
9.
go back to reference Ahima RS, Prabakaran D, Mantzoros C et al (1996) Role of leptin in the neuroendocrine response to fasting. Nature 382:250–252CrossRefPubMed Ahima RS, Prabakaran D, Mantzoros C et al (1996) Role of leptin in the neuroendocrine response to fasting. Nature 382:250–252CrossRefPubMed
10.
go back to reference Challis BG, Coll AP, Yeo GS et al (2004) Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY(3-36). Proc Natl Acad Sci U S A 101:4695–4700CrossRefPubMedPubMedCentral Challis BG, Coll AP, Yeo GS et al (2004) Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY(3-36). Proc Natl Acad Sci U S A 101:4695–4700CrossRefPubMedPubMedCentral
11.
go back to reference Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gruters A (1998) Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 19:155–157CrossRefPubMed Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gruters A (1998) Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 19:155–157CrossRefPubMed
12.
go back to reference Huszar D, Lynch CA, Fairchild-Huntress V et al (1997) Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88:131–141CrossRefPubMed Huszar D, Lynch CA, Fairchild-Huntress V et al (1997) Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88:131–141CrossRefPubMed
13.
go back to reference Vaisse C, Clement K, Guy-Grand B, Froguel P (1998) A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nat Genet 20:113–114CrossRefPubMed Vaisse C, Clement K, Guy-Grand B, Froguel P (1998) A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nat Genet 20:113–114CrossRefPubMed
14.
go back to reference Yeo GS, Farooqi IS, Aminian S, Halsall DJ, Stanhope RG, O’Rahilly S (1998) A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat Genet 20:111–112CrossRefPubMed Yeo GS, Farooqi IS, Aminian S, Halsall DJ, Stanhope RG, O’Rahilly S (1998) A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat Genet 20:111–112CrossRefPubMed
15.
go back to reference Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O’Rahilly S (2003) Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 348:1085–1095CrossRefPubMed Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O’Rahilly S (2003) Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 348:1085–1095CrossRefPubMed
16.
go back to reference Alharbi KK, Spanakis E, Tan K et al (2007) Prevalence and functionality of paucimorphic and private MC4R mutations in a large, unselected European British population, scanned by meltMADGE. Hum Mutat 28:294–302CrossRefPubMed Alharbi KK, Spanakis E, Tan K et al (2007) Prevalence and functionality of paucimorphic and private MC4R mutations in a large, unselected European British population, scanned by meltMADGE. Hum Mutat 28:294–302CrossRefPubMed
17.
go back to reference Challis BG, Pritchard LE, Creemers JW et al (2002) A missense mutation disrupting a dibasic prohormone processing site in pro-opiomelanocortin (POMC) increases susceptibility to early-onset obesity through a novel molecular mechanism. Hum Mol Genet 11:1997–2004CrossRefPubMed Challis BG, Pritchard LE, Creemers JW et al (2002) A missense mutation disrupting a dibasic prohormone processing site in pro-opiomelanocortin (POMC) increases susceptibility to early-onset obesity through a novel molecular mechanism. Hum Mol Genet 11:1997–2004CrossRefPubMed
18.
go back to reference Lee YS, Challis BG, Thompson DA et al (2006) A POMC variant implicates beta-melanocyte-stimulating hormone in the control of human energy balance. Cell Metab 3:135–140CrossRefPubMed Lee YS, Challis BG, Thompson DA et al (2006) A POMC variant implicates beta-melanocyte-stimulating hormone in the control of human energy balance. Cell Metab 3:135–140CrossRefPubMed
19.
go back to reference Raffan E, Dennis RJ, O’Donovan CJ et al (2016) A deletion in the canine POMC gene is associated with weight and appetite in obesity-prone labrador retriever dogs. Cell Metab 23:893–900CrossRefPubMedPubMedCentral Raffan E, Dennis RJ, O’Donovan CJ et al (2016) A deletion in the canine POMC gene is associated with weight and appetite in obesity-prone labrador retriever dogs. Cell Metab 23:893–900CrossRefPubMedPubMedCentral
20.
go back to reference Sutter NB, Ostrander EA (2004) Dog star rising: the canine genetic system. Nat Rev Genet 5:900–910CrossRefPubMed Sutter NB, Ostrander EA (2004) Dog star rising: the canine genetic system. Nat Rev Genet 5:900–910CrossRefPubMed
21.
go back to reference Raffan E, Smith SP, O’Rahilly S, Wardle J (2015) Development, factor structure and application of the Dog Obesity Risk and Appetite (DORA) questionnaire. PeerJ 3, e1278CrossRefPubMedPubMedCentral Raffan E, Smith SP, O’Rahilly S, Wardle J (2015) Development, factor structure and application of the Dog Obesity Risk and Appetite (DORA) questionnaire. PeerJ 3, e1278CrossRefPubMedPubMedCentral
22.
go back to reference Kühnen P, Mischke M, Wiegand S et al (2012) An Alu element-associated hypermethylation variant of the POMC gene is associated with childhood obesity. PLoS Genet 8, e1002543CrossRef Kühnen P, Mischke M, Wiegand S et al (2012) An Alu element-associated hypermethylation variant of the POMC gene is associated with childhood obesity. PLoS Genet 8, e1002543CrossRef
23.
go back to reference Kühnen P, Handke D, Waterland RA et al (2016) Interindividual variation in DNA methylation at a putative POMC metastable epiallele is associated with obesity. Cell Metab 24:502–509CrossRefPubMed Kühnen P, Handke D, Waterland RA et al (2016) Interindividual variation in DNA methylation at a putative POMC metastable epiallele is associated with obesity. Cell Metab 24:502–509CrossRefPubMed
24.
go back to reference Kühnen P, Clement K, Wiegand S et al (2016) Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. N Engl J Med 375:240–246CrossRefPubMed Kühnen P, Clement K, Wiegand S et al (2016) Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. N Engl J Med 375:240–246CrossRefPubMed
25.
go back to reference Greenfield JR, Miller JW, Keogh JM et al (2009) Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med 360:44–52CrossRefPubMed Greenfield JR, Miller JW, Keogh JM et al (2009) Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med 360:44–52CrossRefPubMed
26.
go back to reference Frayling TM, Timpson NJ, Weedon MN et al (2007) A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 316:889–894CrossRefPubMedPubMedCentral Frayling TM, Timpson NJ, Weedon MN et al (2007) A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 316:889–894CrossRefPubMedPubMedCentral
27.
go back to reference Loos RJ (2012) Genetic determinants of common obesity and their value in prediction. Best Pract Res Clin Endocrinol Metab 26:211–226CrossRefPubMed Loos RJ (2012) Genetic determinants of common obesity and their value in prediction. Best Pract Res Clin Endocrinol Metab 26:211–226CrossRefPubMed
28.
Metadata
Title
Genetics of obesity: can an old dog teach us new tricks?
Author
Giles S. H. Yeo
Publication date
01-05-2017
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 5/2017
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-016-4187-x

Other articles of this Issue 5/2017

Diabetologia 5/2017 Go to the issue

Up front

Up front

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine